Since the approval of Vorinostat for refractory cutaneous T-cell lymphoma (CTCL) by the Food and Drug Administration (FDA), numerous HDAC inhibitors (HDACis) have received serious attention during past few years [11, 12]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.